437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 50%
Titel:
437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 50%
Auteur:
Reck, M. Rodriguez-Abreu, D. Robinson, A. Hui, R. Csoszi, T. Fülöp, A. Gottfried, M. Peled, N. Tafreshi, A. Cuffe, S. O'Brien, M.E. Rao, S. Hotta, K. Leiby, M. Lubiniecki, G. Shentu, Y. Rangwala, R. Brahmer, J.